This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Global Partners Making Progress Against Neglected Tropical Diseases, New Report And Scorecard Show

NEW YORK, Jan. 16, 2013 /PRNewswire/ -- Global partners in the fight against neglected tropical diseases (NTDs) have made substantial progress over the past year, with more than 40 countries delivering detailed plans to control and eliminate these diseases and major pharmaceutical companies donating more than one billion treatments to meet 100 percent of drug requests by endemic countries. These successes are outlined in a new report, From Promises to Progress , released today in advance of the first anniversary of the landmark London Declaration, which brought public and private partners together under the shared goal of controlling and eliminating 10 NTDs by 2020.

"The prospects for success have never been so strong," said Dr. Margaret Chan, Director-General of the World Health Organization (WHO). "Many millions of people are being freed from the misery and disability that have kept populations mired in poverty for centuries. Nevertheless, recent progress has revealed unprecedented needs: more nuanced control strategies and new technical tools."

Collaborative efforts among public and private sector organizations have produced major successes in their work to combat NTDs, a group of diseases that disproportionately affect those living in poverty and sicken, disable and disfigure more than one billion people in 149 countries and territories. Notable achievements in 2012 include:   
  • The world's leading pharmaceutical companies provided 1.12 billion treatments for NTDs, an increase of 150 million treatments from 2011. These commitments fully met the increased requests from endemic country partners and removed a key bottleneck to the successful treatment and prevention of NTDs.
  • Twenty-nine countries began receiving albendazole or mebendazole to treat or prevent soil-transmitted helminthiasis, increasing treatments provided with those drugs from 46 million in 2011 to 238 million in 2012.
  • The United Kingdom increased its spending on NTDs from US$24.7 million in 2011 to $42.5 million in 2012, while the U.S. Agency for International Development has steadily increased its donations over the past several years, reaching $89 million in 2012. These donors and others committed funds to support integrated programs, scale up and expand existing programs, increase funding available for disease mapping, improve program strategies through research and develop new tools.
  • More than 40 countries developed multi-year integrated NTD plans, and Brazil, Burundi, Cameroon and Honduras launched their plans.
  • Oman became the first previously endemic country verified as trachoma-free, with more expected later in 2013.
  • Two NTD diagnostic tests received regulatory approval: the first ever lateral flow test for sleeping sickness was commercially launched in December 2012, and a new rapid diagnostic test for lymphatic filariasis will become commercially available in the first half of 2013.

"These numbers are more than just drugs delivered or funds committed. They ultimately mean that millions of people have been spared pain and suffering from these debilitating diseases," said Christopher A. Viehbacher, CEO of Sanofi. "Through new and innovative partnerships, we can continue to help break the cycle of poverty and overcome the burden of NTDs."

Today, WHO also launched its second NTD report, Sustaining the Drive to Overcome the Global Impact of Neglected Tropical Diseases, which discusses the path to achieving 2020 goals, identifies challenges and proposes plans to address each disease. Together, these reports offer a united way forward for the NTD community.

To coordinate efforts and monitor progress, partners developed a scorecard to track the London Declaration pledges. Released today with the report, the London Declaration Scorecard captures progress made and where efforts must improve if partners hope to reach the 2020 goals. In addition, the scorecard and report set benchmarks for success in 2013 and beyond that would help put the world on a steady trajectory toward those goals.

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
SYM TRADE IT LAST %CHG

Markets

DOW 17,683.58 -46.53 -0.26%
S&P 500 2,068.76 -8.02 -0.39%
NASDAQ 4,991.94 -17.2740 -0.34%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs